Received Jan 12, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | 3 | 47XP4 | — |
an adult patient received a pediatric dose; an adult patient received a pediatric dose; This non-serious case was reported by a nurse via call center representative and described the occurrence of adult use of a child product in a 28-year-old female patient who received HBV (Engerix B pediatric) (batch number 47XP4) for prophylaxis. On 05-JAN-2026, the patient received the 3rd dose of Engerix B pediatric. On 05-JAN-2026, an unknown time after receiving Engerix B pediatric, the patient experienced adult use of a child product (Verbatim: an adult patient received a pediatric dose) and underdose (Verbatim: an adult patient received a pediatric dose). The outcome of the adult use of a child product and underdose were not applicable. Additional Information: GSK receipt date: 07-JAN-2025 The reporter consented to follow up. The vaccine administration facility was the same as primary reporter. The batch number was not provided upon follow- up with the reporter.